Guangjun Nie

Dr. Guangjun NIE is a principal investigator and deputy director at the National Center for Nanoscience and Technology of China. He obtained his doctoral degree from the Institute of Biophysics, Chinese Academy of Sciences, in 2002. After that, he conducted postdoctoral research at McGill University in Canada. In 2008, he joined the National Center for Nanoscience and Technology. He was the founding director of Materials Biology and Precision Therapy at the Chinese Biophysical Society, the director of the Nanotechnological Oncology, Chinese Anticancer Association, and council member of the Chinese Society for Biomaterials, a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and a Fellow of the Royal Society of Chemistry (FRSC) of the UK. He is the Executive Editor of Nano Letters, the Associate Editor of Life Medicine, and a member of the editorial board of Fundamental Research and Nano Today.

His research focuses on nanomedicines for sensing and regulating the disease microenvironment, leading to significant advancements in areas such as vascular, ECM, and immune regulation of diseases, drug-delivery nanorobots, and nanovaccines. He has authored over 340 peer-reviewed papers in prestigious journals, including Nature Biotechnology and Science Translational Medicine, and secured 30 patents, successfully transferring three of them to biotech companies. His papers have accumulated over 32,000 citations, with an H-index of 99, according to Google Scholar. He has received numerous prestigious awards, including the Yiling Biomedical Youth Award from the Chinese Pharmaceutical Association in 2016, the Second Prize of the Science and Technology Award from the same association in 2018, and recognition as one of the Top Ten Scientific Advances in China in 2018. Additionally, he was honored with the First Prize of the Beijing Natural Science Award in 2020, the First Prize of the Tianjin Science and Technology Progress Award, the First Prize of the Science and Technology Award from the Chinese Anti-Cancer Association, and the First Prize of the Contribution Award for the Overseas Chinese Community in 2022, the First Prize of the Biomaterials Society Science and Technology in 2025.